Skip to main content

Hereditary Angioedema clinical trials at UC Health

3 in progress, 0 open to eligible people

Showing trials for
  • A Study to Assess the Clinical Efficacy of IONIS-PKK-LRx in Participants With Hereditary Angioedema

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the clinical efficacy, safety, and tolerability of IONIS-PKK-LRx in participants with hereditary angioedema (HAE) type 1 (HAE-1), HAE type 2 (HAE-2), or HAE with normal C1-inhibitor (C1-INH) and to evaluate the effect of IONIS-PKK-LRx on plasma prekallikrein (PKK) and other relevant biomarkers.

    at UCSD

  • CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

    Sorry, not currently recruiting here

    This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedema

    at UCSD

  • Study to Evaluate the Real-world Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)

    Sorry, not currently recruiting here

    This observational, prospective study aims to evaluate the real-world effectiveness of lanadelumab in participants with hereditary angioedema (HAE). Participant-reported attack diaries and patient-reported outcomes (PROs) as well as physician assessments at standard of care (SoC) visits will be used to describe HAE attack rates, treatment patterns, healthcare utilization and participant quality of life.

    at UCSD

Last updated: